Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 7/20 | 0.69 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.61 |
| ▸ | ESRRA | P11474 | 2/20 | 0.61 |
| ▸ | MMP3 | P08254 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 3/20 | 0.55 |
| ▸ | CRHBP | P24387 | 1/20 | 0.55 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.55 |
| ▸ | IDH1 | O75874 | 1/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SI | P14410 | 1/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504421 | 0.82 | ESRRA (0.77) | CISD1ESRRAGSK3BHPGD | |
| SCHEMBL5504425 | 0.82 | ESRRA (0.77) | CISD1ESRRAGSK3BHPGD | |
| SCHEMBL12892061 | 0.80 | CISD1 (0.61) | ADAMTS5CISD1ESRRAMMP13GSK3B | |
| SCHEMBL13749931 | 0.78 | CISD1 (1.00) | ADAMTS5CISD1MMP3MMP13GSK3B | |
| SCHEMBL8271091 | 0.76 | ESRRA (1.00) | ESRRA | |
| SCHEMBL5507657 | 0.76 | ESRRA (1.00) | ESRRA | |
| SCHEMBL5507653 | 0.76 | ESRRA (1.00) | ESRRA | |
| SCHEMBL13881915 | 0.75 | LMNA (0.55) | HPGD | |
| SCHEMBL7969788 | 0.74 | MMP3 (0.67) | ESRRAMMP3MMP13GSK3BCRHBP | |
| SCHEMBL8188463 | 0.74 | ADAMTS5 (1.00) | ADAMTS5CISD1MMP3MMP13GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | ADAMTS5 3693/4885CISD1 1672/4885ESRRA 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.